Navigation Links
Multi-functional anti-inflammatory/anti-allergic developed by Hebrew University researcher

Jerusalem, Sept. 6, 2012 A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

The researcher is Saul Yedgar, who is the Walter and Greta Stiel Professor of Heart Studies at the Institute for Medical Research Israel-Canada at the Hebrew University Faculty of Medicine.

Inflammatory/allergic diseases affect billions of people worldwide, and treatments for these conditions are a major focus of the pharmaceutical industry. The most common drugs currently used to treat these numerous diseases are steroids, which are potent but are associated with severe side effects. These include metabolic changes (weight gain, increased blood pressure, diabetes), organ-specific effects (glaucoma, cataracts, bone fragility), and even psychotrophic side effects (depression, psychosis).

For decades, alternatives, such as biological NSAIDs (non-steroidal alternative anti-inflammatory drugs) have been the focus of the pharmaceutical industry. The resulting drugs have been commercially successful, but have not produced genuine alternatives to steroids due to their limitations. Synthetic NSAIDs are less potent and have their own serious side effects, including cardiovascular disorders, stomach bleeding and respiratory disorders. The biological drugs are costly and, must be injected and have rare but very severe side effects.

Inflammatory/allergic diseases present different symptoms affecting different organs, such as skin inflammations (dermatitis, psoriasis); airway injury and allergy (asthma, cystic fibrosis, allergic rhinitis); osteoarthritis and rheumatoid arthritis; intestinal inflammation (ulcerative colitis, Crohn's disease); central nervous system inflammation (multiple sclerosis), as well as atherosclerosis and cancer metastasis.

What they have in common is that all of them share biochemical mechanisms. A key one among them is the action of an enzyme family (PLA2) that initiates the production of a cascade of pro-inflammatory mediators involved in the induction and propagation of the diverse inflammatory diseases.

In Prof. Yedgar's lab at the Hebrew University, he and his associates have designed and constructed an entirely novel synthetic generation of drugs that control the PLA activity and the subsequent cascade of pro-inflammatory mediators, thereby providing multi-functional, anti-inflammatory drugs (MFAIDs).

MFAIDs have shown excellent safety and were found efficient in treating diverse inflammatory/allergic conditions in animal models, using different ways of administration oral, rectal, intravenous, inhaled and injected. These conditions included sepsis, inflammatory bowel diseases, asthma and central nervous system inflammation.

In particular, in two clinical studies MFAIDs have been shown to be safe and efficient in treating contact dermatitis, when incorporated into skin cream, and allergic rhinitis, when administered as a nasal spray.

This platform technology has been exclusively licensed from the Hebrew University through the university's Yissum Technology Transfer Company to Morria Biopharmaceuticals PLC (a British company), which is currently developing these drugs to treat inflammatory diseases of the airways (hay-fever, cystic fibrosis), the skin (eczema), the eye (conjunctivitis) and the gut (colitis, Crohn's disease).

For his groundbreaking work, Prof. Yedgar was one of the winners of this year's Kaye Innovation Awards at the Hebrew University. The Kaye Awards have been given annually since 1994. Isaac Kaye of England, a prominent industrialist in the pharmaceutical industry, established the awards to encourage faculty, staff and students of the Hebrew University to develop innovative methods and inventions with good commercial potential which will benefit the university and society. The awards were presented this year during the annual meeting of the Hebrew University Board of Governors.

Contact: Jerry Barach
The Hebrew University of Jerusalem

Related medicine news :

1. Heroes of Chemistry: Developed new drugs and technology to cut heating and cooling bills
2. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
3. New Facebook app to detect pedophiles and criminals developed by Ben-Gurion U. researchers
4. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
5. FDA clears test developed in partnership with VCU researcher
6. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
7. Power generation technology based on piezoelectric nanocomposite materials developed by KAIST
8. Research shows efficacy of treatment model developed at Women & Infants
9. University of Hawaii cancer researchers discover gene defect responsible for cancer syndrome
10. Oxford University Press acquires American Journal of Hypertension
11. Queens University Belfast wins national environment award
Post Your Comments:
Related Image:
Multi-functional anti-inflammatory/anti-allergic developed by Hebrew University researcher
(Date:10/13/2015)... ... ... In an age where the cost of energy is rising, Susquehanna Health’s ... 2009. The Williamsport Regional Medical Center (WRMC) campus has grown 50 percent since 2010, ... , According to Facilities Management Administrative Director Dieter Reichmann, this is the result of ...
(Date:10/13/2015)... ... 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood , comments ... research, which was conducted at the Dental Institute at King's College London in the ... during pregnancy and future dental health in the child. For years, researchers have long ...
(Date:10/13/2015)... New York, NY (PRWEB) , ... October 13, 2015 , ... ... Android®. The app helps individuals find others to train with, participate in local fitness ... the App Store and Google Play. , “As high medical costs drive us to ...
(Date:10/13/2015)... ... 13, 2015 , ... Leading Internet marketing product review website ... Academy" training course . Singal's new program, in which he reveals his strategies ... the Internet are weighing in with reviews. , "Considering the fairly high number ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec Products, ... Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference will take ... and will unite customers, partners, WennSoft team members and sponsors to facilitate the ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... -- Data Science Automation (DSA), a system integration and automation engineering ... in the United Kingdom (UK) as ... . The decision to open the new office comes ... customers in the medical device industry throughout the UK. ... have had tremendous success over the last several years in ...
(Date:10/13/2015)... 13, 2015  SRI International has been awarded ... over five years by the National Institute of ... National Institutes of Health, for the development of ... effects of radiation exposure. Under this multi-year contract, ... International will provide services, facilities, expertise and capabilities ...
(Date:10/13/2015)... 2015  Nanomedical Diagnostics, a biotech company developing ... diagnostics, announces the completion of a Series A ... Ventures. --> ... monitoring and diagnostic platforms that empower individuals to ... will enable the company to commercially release AGILE ...
Breaking Medicine Technology: